Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9679675 | 0.85 | KMT2A (0.43) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL9678803 | 0.84 | KMT2A (0.50) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL9680708 | 0.83 | LPAR1 (0.49) | KMT2AMEN1SMN1; SMN2SOAT2SOAT1 | |
| SCHEMBL9851048 | 0.82 | KMT2A (0.54) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL9678925 | 0.79 | LPAR1 (0.49) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9680221 | 0.79 | KMT2A (0.49) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL9679644 | 0.78 | KMT2A (0.44) | KMT2AMEN1LMNASMN1; SMN2SOAT2 | |
| SCHEMBL9680252 | 0.77 | LPAR1 (0.58) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9680261 | 0.76 | CYP2C19 (0.54) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL9680196 | 0.74 | KMT2A (0.45) | KMT2AMEN1LMNASMN1; SMN2SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0415413-A1 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-03-06 | — | — | EP | claimed |
| US-5153226-A | Administering as anticholesterol agents, for atherosclerosis | WARNER-LAMBERT COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0415413-A1 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |